Veracyte Prices IPO, Targets $65M in Gross Proceeds | GenomeWeb

NEW YORK (GenomeWeb News) – Veracyte today priced its initial public offering of 5 million shares at $13 per share.

The South San Francisco, Calif.-based firm is expected to begin trading today on the Nasdaq Global Market under the symbol "VCYT." It will realize gross proceeds of $65 million from the offering, though the underwriters of the IPO have a 30-day option to purchase 750,000 additional shares to cover any over-allotments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.